223 related articles for article (PubMed ID: 24728492)
1. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Jiang Y; Yuan Q; Fang Q
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K
Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Mahaffey CM; Davies AM; Lara PN; Pryde B; Holland W; Mack PC; Gumerlock PH; Gandara DR
Clin Lung Cancer; 2007 Nov; 8(9):548-53. PubMed ID: 18186959
[TBL] [Abstract][Full Text] [Related]
5. Second-Line Therapy for Advanced NSCLC.
Weiss JM; Stinchcombe TE
Oncologist; 2013; 18(8):947-53. PubMed ID: 23918070
[TBL] [Abstract][Full Text] [Related]
6. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
7. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
8. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
[TBL] [Abstract][Full Text] [Related]
10. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Pan F; Tian J; Zhang X; Zhang Y; Pan Y
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1397-408. PubMed ID: 21796416
[TBL] [Abstract][Full Text] [Related]
12. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
[TBL] [Abstract][Full Text] [Related]
15. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Jackman DM; Miller VA; Cioffredi LA; Yeap BY; Jänne PA; Riely GJ; Ruiz MG; Giaccone G; Sequist LV; Johnson BE
Clin Cancer Res; 2009 Aug; 15(16):5267-73. PubMed ID: 19671843
[TBL] [Abstract][Full Text] [Related]
16. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
[TBL] [Abstract][Full Text] [Related]
18. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Zhang W; Zhang W; Wang L; Zheng J; Xiao F
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
Lee WY; Chen PC; Wu WS; Wu HC; Lan CH; Huang YH; Cheng CH; Chen KC; Lin CW
Int J Cancer; 2017 Nov; 141(9):1921-1931. PubMed ID: 28710768
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
